Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Corvus Pharmaceuticals was founded in 2015 with a focus on developing novel, immune system-focused drugs. The company grew out of research at the University of California San Francisco and Stanford University.

Corvus is dedicated to improving the lives of cancer patients through the development of life-saving immuno-oncology therapies.

Corvus will become the leading provider of innovative, safe, and effective therapies that target a wide range of cancer types.

Corvus is dedicated to improving the lives of cancer patients through the development of life-saving immuno-oncology therapies.

Corvus will become the leading provider of innovative, safe, and effective therapies that target a wide range of cancer types.

Corvus Pharmaceuticals

Share

Contacts

Follow Us

Corvus Pharmaceuticals

Share

Contacts

Follow Us